Dieses Ergebnis aus Springer Nature Journals kann Gästen nicht angezeigt werden. Login für vollen Zugriff.

Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial

Title:	Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial
Authors:	Zhu, Zaihua^Aff1; Xue, Yu^Aff1; Chu, Tianshu^Aff2; Hu, Jiankang^Aff3; Gou, Wei^Aff4; Zhang, Ning^Aff5; Li, Juan^Aff6; Yu, Jing^Aff7; Li, Rongping^Aff8; Li, Rongbin^Aff9; Qian, Long^Aff10; Duan, Xinwang^Aff11; Duan, Lihua^Aff12; Xu, Qian^Aff13; Gu, Fei^Aff13; Lian, Yuling^Aff13; Zhang, Xu^Aff13; Zou, Hejian^{Aff1, IDs12325026036116_cor1}
Source:	Advances in Therapy. :1-19
Database:	Springer Nature Journals